Effect of pH on the in vitro susceptibility of planktonic and biofilm-grown Proteus mirabilis to the quinolone antimicrobials

Journal of Applied Microbiology

Volumn 115, Issue 2, 2013, Pages 382-389

  Irwin, N J ^a   Mccoy, C P ^a   Carson, L ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Antibiotics; Antimicrobials; Biofilms; Mechanism of action

Indexed keywords

ALKALINITY; BIOFILMS; CATHETERS; PH EFFECTS;

ANTIMICROBIAL; BACTERICIDAL ACTIVITY; BACTERIOSTATIC; EFFECT OF PH; IN-VITRO; MECHANISM OF ACTION; NALIDIXIC ACID; PROTEUS MIRABILIS; QUINOLONES; URINARY CATHETERS;

ANTIBIOTICS;

CIPROFLOXACIN; NALIDIXIC ACID; NORFLOXACIN;

ANTIBIOTICS; BACTERIUM; BIOFILM; ENZYME; ENZYME ACTIVITY; IONIZATION; PATHOGEN; PH;

ALKALINITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BIOFILM; CATHETER INFECTION; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PH; PLANKTON; PROTEUS MIRABILIS; URINARY CATHETER;

BACTERIA (MICROORGANISMS); MIRABILIS; PROTEUS MIRABILIS;

EID: 84880617573     PISSN: 13645072     EISSN: 13652672     Source Type: Journal    
DOI: 10.1111/jam.12241     Document Type: Article

References (41)

1. Adnan, M., Morton, G., Singh, J. and Hadi, S. (2010) Contribution of rpoS and bolA genes in biofilm formation in Escherichia coli K-12 MG1655. Mol Cell Biochem 342, 207-213.
2. Babic, S. (2007) Determination of pKa values of active pharmaceutical ingredients. Trends Anal Chem 26, 1043-1061.
3. Bauernfeind, A. (1983) In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol 2, 111-115.
4. Bauernfeind, A. and Petermuller, C. (1983) Progress in chemotherapeutic heterocyclic carbonic-acids. Drugs Exp Clin Res 9, 545-553.
5. Bester, E., Kroukamp, O., Wolfaardt, G.M., Boonzaaier, L. and Liss, S.M. (2010) Metabolic differentiation in biofilms as indicated by carbon dioxide production rates. Appl Environ Microbiol 76, 1189-1197.
6. Carson, L., Chau, P.K.W., Earle, M.J., Gilea, M.A., Gilmore, B.F. and Gorman, S.P. (2009) Antibiofilm activities of 1-alkyl-3-methylimidazolium chloride ionic liquids. Green Chem 11, 492-497.
7. Ceri, H., Olson, M.E., Stremick, C., Read, R.R., Morck, D. and Buret, A. (1999) The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37, 1771-1776.
8. Chevalier, J., Mallea, M. and Pages, J.M. (2000) Comparative aspects of the diffusion of norfloxacin, cefepime and spermine through the F porin channel of Enterobacter cloacae. Biochem J 348, 223-227.
9. Choi, S.Y., Rodriguez, H., Mirjafari, A., Gilpin, D.F., McGrath, S., Malcolm, K.R., Tunney, M.M., Rogers, R.D. et al. (2011) Dual functional ionic liquids as plasticisers and antimicrobial agents for medical polymers. Green Chem 13, 1527-1535.
10. Crumplin, G.C. (1975) Nalidixic acid: an antibacterial paradox. Antimicrob Agents Chemother 8, 251-261.
11. Crumplin, G.C. and Smith, J.T. (1976) Nalidixic acid and bacterial chromosome replication. Nature 260, 643-645.
12. Delcour, A.H. (2009) Outer membrane permeability and antibiotic resistance. Biochimica Et Biophysica Acta-Proteins and Proteomics 1794, 808-816.
13. Drlica, K. (2008) Quinolone-mediated bacterial death. Antimicrob Agents Chemother 52, 385-392.
14. Foxman, B. (2010) The epidemiology of urinary tract infection. Nat Rev Urol 7, 653-660.
15. Giamarellou, H. and Jackson, G.G. (1975) Antibacterial activity of cinoxacin in vitro. Antimicrob Agents Chemother 7, 688-692.
16. Haas, W., Pillar, C.M., Hesje, C.K., Sanfilippo, C.M. and Morris, T.W. (2011) In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride. J Antimicrob Chemother 66, 840-844.
17. Hirai, K., Aoyama, H., Irikura, T., Iyobe, S. and Mitsuhashi, S. (1986) Differences in susceptibility to quinolones of outer-membrane mutants of Salmonella-typhimurium and Escherichia-coli. Antimicrob Agents Chemother 29, 535-538.
18. Hooper, D. (2002) Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2, 530-538.
19. Ito, A. (1980) In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother 17, 103-108.
20. Jacoby, G.A. (2011) Review of the Quinolone Family. Antibiot Discov Dev 2, 119-146.
21. Kershaw, M.J. (1975) The antibacterial and pharmacological activity of oxolinic acid (Prodoxol). J Antimicrob Chemother 1, 311-315.
22. Lemaire, S., Tulkens, P.M. and Van Bambeke, F. (2011) Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother 55, 649-658.
23. Lesher, G.Y., Froelich, E.J., Gruett, M.D., Bailey, J.H. and Brundage, R.P. (1962) 1, 8-Naphthyridine derivatives: a new class of chemotherapeutic agents. J Med Pharm Chem 5, 1063-1068.
24. Lewin, C.S. (1991) The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment. Eur J Clin Microbiol Infect Dis 10, 240-248.
25. Lewis, K. (2007) Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5, 48-56.
26. Lumish, R.M. (1975) Cinoxacin: in vitro antibacterial studies of a new synthetic organic acid. Antimicrob Agents Chemother 7, 159-163.
27. McKenney, D. and Allison, D.G. (1997) Influence of growth rate and nutrient limitation on susceptibility of Burkholderia cepacia to ciprofloxacin and tobramycin. J Antimicrob Chemother 40, 415-417.
28. Mobley, H.L.T. (1996) Virulence of Proteus mirabilis. In Urinary Tract Infections: Molecular Pathogenesis and Clinical Management ed. Mobley, H.L.T. and Warren, J.W. pp. 245-269. Washington, DC: ASM Press.
29. Pankuch, G.A., Jacobs, M.R. and Appelbaum, P.C. (1994) Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother 38, 2065-2072.
30. Senior, B.W. (1983) Proteus morgani is less frequently associated with urinary tract infections than Proteus mirabilis-an explanation. J Med Microbiol 16, 317-322.
31. Stevens, P.J.E. (1980) Bactericidal effect against Escherichia coli of nalidixic acid and four structurally related compounds. J Antimicrob Chemother 6, 535-542.
32. Stewart, P.S. and Costerton, J.W. (2001) Antibiotic resistance of bacteria in biofilms. Lancet 358, 135-138.
33. Stewart, P. and Franklin, M. (2008) Physiological heterogeneity in biofilms. Nat Rev Microbiol 6, 199-210.
34. Stickler, D.J. (2006) Modulation of crystalline Proteus mirabilis biofilm development on urinary catheters. J Med Microbiol 55, 489-494.
35. Stickler, D.J., Morris, N., Moreno, M.C. and Sabbuba, N. (1998) Studies on the formation of crystalline bacterial biofilms on urethral catheters. Eur J Clin Microbiol Infect Dis 17, 649-652.
36. Tallgren, L.G. (2009) The effect of varying the pH level upon the sensitivity of urinary bacteria to antibiotics. Acta Med Scand 178, 543-551.
37. Teoh Chan, C.H. (1985) Laboratory evaluation of enoxacin: comparison with norfioxacin and nalidixic acid. J Antimicrob Chemother 15, 45-52.
38. Walker, K.E., Moghaddame-Jafari, S., Lockatell, C.V., Johnson, D. and Belas, R. (1999) ZapA, the IgA degrading metalloprotease of Proteus mirabilis, is a virulence factor expressed specifically in swarmer cells. Mol Microbiol 32, 825-836.
39. Wayne, P.A. (1999) Methods for Determining Bactericidal Activity of Antimicrobial Agents- Eighth edition: Approved Standard M26-A. Pennsylvania: Clinical and Laboratory Standards Institute.
40. Wayne, P.A. (2012) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically- Ninth Edition: Approved Standard M07-A9. Pennsylvania: Clinical and Laboratory Standards Institute.
41. Wolfson, J.S. (1985) The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 28, 581-586.